Louis Williams

Hematologist/oncologist, Staff Physician @ClevelandClinic, plasma cell & genomics enthusiast, ex-VC analyst, dad, views my own, #myeloma, #amyloidosis, #NSNO

[Raj Chakraborty @rajshekharucms]

The treatment landscape for AL #Amyloidosis has been transformed—but how do we assess prognosis and progression in the current era? We reviewed the current evidence on prognostic factors and biomarkers for hematologic and organ progression in this special report, out today in @BloodPortfolio. @Amyloidosis_ARC @YevgeniyBr @awechalekar @MathewMaurer @kristennhsu
https://t.co/UwdIaMm0d6

[Hamlet Gasoyan @HamletGasoyan]

📊 Our real-world data demonstrate the association of sociodemographic and clinical factors with multiple #myeloma therapy selection and improved 5-year OS in clinical practice compared to historical trends.
@FaizAnwerMD1 @LouisWilliamsMD @MRothbergMD

https://t.co/vLVhP8zKjt

[Louis Williams @LouisWilliamsMD]

@Bethfaiman discussing the changing patient journey in #myeloma at the @IMFmyeloma patient and family seminar in Cleveland. One of the best in the business. @jmikhaelmd #mmsm

[Louis Williams @LouisWilliamsMD]

@FinlaysonMac @Bethfaiman @kansagraMD @BloodCancerJnl @HossamAli_MD @FaizAnwerMD1 Sounds like she has really persevered with UHR disease. I’m sorry the journey has been so difficult. We need to be more inclusive in trial design and to focus as much as we can on the higher risk subsets. We don’t make progress until all pts make progress.

[Robert Z. Orlowski @Myeloma_Doc]

#Myeloma Paper of the Day: Case series of relapsed/refractory myeloma pts w/ renal impairment treated w/ talquetamab finds ORR at day 30 was 6/12 (50%), median PFS 8.48 months and good OS w/ manageable toxicity even in dialysis-dependent patients: https://t.co/NFWYQTPJTu. #mmsm

[International Myeloma Foundation @IMFmyeloma]

@LouisWilliamsMD @Bethfaiman @domenica76 We're so glad to hear that, Dr Williams. Thank you for saying that. Just going to drop this link here for the Las Voces de Mieloma support group page. This group meets on the third Tuesday of every month. https://t.co/8r7iUv6CDM

[International Myeloma Foundation @IMFmyeloma]

@Bethfaiman @LouisWilliamsMD @domenica76 ❤️ Thanks for helping spread this information, Beth!
Third Tuesday of every month is when the Las Voces de Mieloma support group meets. https://t.co/8r7iUv6CDM

[Beth Faiman PhD @Bethfaiman]

Thank you @Myeloma_Doc for highlighting our important paper, which highlights that #talquetamab can be considered in #myeloma patients with severe #renal insufficiency, ESRD w/ appropriate supportive care! @HossamAli_MD @LouisWilliamsMD @FaizAnwerMD1 @dbasali @khouri_jack #mmsm

[Louis Williams @LouisWilliamsMD]

@Bethfaiman @IMFmyeloma @domenica76 Have to be honest - I didn’t know much about Las Voces before being invited. Very good support Spanish language content and an audience of international patients with really good questions. I will definitely be sharing with my Spanish speaking patients.

[Henry C Fung| MM, lymphoma, leukemia & CART @HenrychihangFu1]

We’ve talked about t(11;14).
We’ve covered t(4;14).

Today: t(14;16) myeloma 🧬

Same disease label.
Very different behavior.

🧲 Early phase (MAF-driven):
• Strong adhesion to bone marrow (VCAM1/integrins)
• “Sticky” → difficult aspirate, clotty marrow
• Patchy involvement → MRD can mislead

👉 Niche-dependent biology
→ IMiD / PI / Dara work well

But the story doesn’t end there.

🚀 With evolution:
• Loss of adhesion dependence
• Genomic complexity (TP53, etc.)
• Extramedullary disease (EMD)

👉 Niche-independent biology
→ IMiD / PI less effective
→ CAR-T & bispecifics make more sense

This is the paradox:
“Sticky” early…
but prone to escape later

t(14;16) isn’t just high-risk—
it’s an evolving disease.

Adhesion → Evolution → Escape

Dr Fun + G

[Louis Williams @LouisWilliamsMD]

Thank you to @IMFmyeloma for inviting me to speak on Las Voces de Mieloma. Happy to share our Spanish language discussion about up front treatment of NDMM and renal disease for patients and caregivers. It was a pleasure. @Bethfaiman @jmikhaelmd

https://t.co/upp79NFfIi

#mmsm

[International Myeloma Foundation @IMFmyeloma]

"Does getting bispecific therapy before CAR-T make CAR-T less effective?"
@Bethfaiman explains what we know.
Drop your questions below and save this for later. #AskTheIMF @jmikhaelmd

[Louis Williams @LouisWilliamsMD]

For those with Spanish speaking #mmsm patients or families who might be interested in learning more about renal disease in myeloma, please pass this along.

https://t.co/BmhMJWOkUc

[Louis Williams @LouisWilliamsMD]

@duakhan128 @johnhanna0 That is the most important question. We are likely to need collaborators and a larger validation cohort. The upcoming manuscript will address some of these issues

[Becky Bosley @MidAtlanticMSG]

Honored to be speaking at the @IMFmyeloma 2026 Patient & Family Seminar in #Cleveland with some fantastic voices in the #myeloma community! Join us on 5/1 – 5/2 to learn about the latest in myeloma and connect with our community. Register here: https://t.co/4FIPatc3Re

[Beth Faiman PhD @Bethfaiman]

Thanks, @MidAtlanticMSG!!! Come see @LouisWilliamsMD and @JasonValent1 @IMFsupport @jmikhaelmd and others share #myeloma updates for
Patients, and families on ‘ay 1-2,2026 in #cleveland! All are welcome. Hope to see you there!! #mmsm

[Gareth Morgan @DrGarethMorgan1]

Been a big year for waldenstrom’s with many new insights. @Perlmutter_CC

[Rahul Banerjee, MD, FACP @RahulBanerjeeMD]

1/ Extremely appreciative of @JCO_ASCO @SLentzsch for opportunity to write about #downwithdex in myeloma #MMsm and AL amyloidosis.

Quite a history going back >70 years to observations that ACTH infusions lowered M-spike 🤯

We've come a long way since then, but more to go! 🧵